The Roundup Cases Are at a Fork: A $7 Billion Deal and a Supreme Court Showdown

The Roundup litigation has been grinding for years, more than 100,000 claims, roughly ten billion dollars already paid out, a long string of jury verdicts swinging from modest to staggering. In 2026 it arrived at a genuine fork in the road, with two huge developments converging at once: a proposed multibillion-dollar class settlement that would resolve most of the remaining and future claims, and a U.S. Supreme Court case that could eliminate the right to bring these lawsuits at all. Either could reshape the litigation. Together, they make 2026 the year the whole thing may turn.

Here's a neutral map of where it stands: what the cases claim, the science fight underneath them, the proposed settlement, and the Supreme Court question that hangs over everything.

What the lawsuits claim

Roundup is a glyphosate-based weedkiller, originally made by Monsanto, which the German company Bayer acquired in 2018 for around 63 billion dollars, inheriting the litigation along with it. The lawsuits allege that exposure to glyphosate, especially heavy or prolonged exposure, caused non-Hodgkin lymphoma, a cancer of the lymphatic system, and that the manufacturer failed to warn users of the risk.

Bayer has consistently and vigorously disputed the cancer claims, pointing to decades of studies and, crucially, to regulators. The position rests heavily on the fact that the U.S. Environmental Protection Agency has concluded glyphosate is unlikely to be carcinogenic to humans when used as directed, and approved the Roundup label without a cancer warning. The plaintiffs' side leans on a different scientific authority: in 2015, the World Health Organization's International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans," a finding that essentially launched the wave of litigation. That conflict, between the EPA's "unlikely" and IARC's "probably," is the scientific fault line the entire fight runs along, and the EPA's glyphosate assessment is central to the company's defense.

The scale, and the verdicts

The numbers are large in every direction. More than 100,000 claims have been filed over the years. Bayer has already paid roughly ten billion dollars resolving earlier rounds of litigation, and has set aside billions more in provisions for what remains, with tens of thousands of cases still pending.

The jury verdicts have been the litigation's dramatic engine. Trials have produced awards ranging from modest sums to truly enormous ones, including verdicts in the hundreds of millions and, in at least one recent case, into the billions before the inevitable appeals and reductions. These verdicts swing both ways, Bayer has won trials too, and large awards are frequently cut down on appeal, but the run of big plaintiff wins is what has kept the pressure on the company and driven it to seek a way out. The financial strain has been real enough that Bayer's leadership has tied it to the company's struggles since the Monsanto acquisition, and the company has at points suggested it might pull glyphosate from the U.S. market if the litigation can't be resolved.

The proposed $7.25 billion class settlement

The first of 2026's two big developments is a proposed class-action settlement, reported at around 7.25 billion dollars, that won preliminary approval from a Missouri state court early in the year. It's designed to resolve both current claims and future ones, people who used Roundup and may be diagnosed with non-Hodgkin lymphoma down the line, through a long-term claims program funded by capped annual payments over a period of years, with payouts determined on a tiered basis reflecting factors like age and the extent of exposure.

What makes this notable, and contentious, is the mechanism. As we discuss in mass tort vs class action, Roundup has functioned as a classic mass tort, tens of thousands of individual cases. Resolving it through a class-action settlement, which binds class members unless they opt out by a deadline, is a different and more sweeping approach, and it's drawn objections. Critics have argued the deal runs roughshod over due-process rights, particularly by binding future claimants, people not yet sick, who can't fully evaluate a settlement of an injury they don't yet have. An earlier, different class settlement proposal collapsed years ago over similar concerns, so the question of whether this one survives its challenges is genuinely open. Class members were given a window to opt out if they wanted to preserve their right to sue individually, and the deal's ultimate fate depends on clearing the objections and the approval process.

The Supreme Court case that could end it all

The second development is the one that could make the settlement, and much of the litigation, beside the point. The U.S. Supreme Court agreed to hear Monsanto v. Durnell, a case arising from a Missouri plaintiff's verdict, and heard oral arguments in April 2026. The question it presents is the one Bayer has been trying to get answered in its favor for years: federal preemption.

Here's the legal heart of it. A federal statute, the Federal Insecticide, Fungicide, and Rodenticide Act, governs pesticide labeling, and the EPA, acting under it, approved Roundup's label without a cancer warning and has maintained glyphosate is unlikely to cause cancer. Bayer's argument is that this federal regime preempts, overrides, state-law claims that the company failed to warn of a cancer risk. If federal law approved a label with no warning, the argument goes, a state-law jury can't punish the company for not including one, because federal law arguably wouldn't even permit the company to add a warning the EPA didn't require. A ruling for Bayer on this question could largely end the Roundup litigation, by knocking out the failure-to-warn theory that underpins most of the cases, and would reach beyond Roundup to pesticide litigation generally.

The case got to the Court because the lower courts split: a federal appeals court ruled in Bayer's favor on preemption, while others had gone the other way, and the Supreme Court tends to take cases that resolve such splits. The Court had declined a similar Bayer request years earlier, but the circuit split changed the calculus. At oral argument the justices appeared divided, with some receptive to the argument that the company can still be sued under state law despite the federal regulator's safety conclusions, and others more sympathetic to Bayer, so the outcome is genuinely uncertain pending the decision. This is the same federal-preemption theory that surfaces in other mass torts, including the Depo-Provera litigation, where a manufacturer argues FDA regulation shields it, a recurring and consequential defense in product cases.

The political layer

Worth noting neutrally, because it's part of the 2026 picture: the litigation has acquired a political dimension. The federal executive branch weighed in on the company's side in the Supreme Court case, a reversal from the prior administration's position, and there have been executive actions and proposed legislative provisions touching glyphosate and pesticide labeling, including efforts to establish uniform national pesticide labels that would bear on the preemption question. A handful of states have passed laws aimed at barring or limiting these suits, while other voices, including some aligned with food-and-health movements, have pushed the other way. The result is that Roundup's fate is being contested not only in the courts but in the political and regulatory arena, which adds another layer of uncertainty to where it lands.

Where this leaves things in 2026

So the honest snapshot. The Roundup litigation sits at a fork. On one path, the proposed 7.25 billion dollar class settlement survives its objections and approval process and resolves the bulk of current and future claims through a tiered, long-term payment program, the way these things, per how mass tort settlements pay out, typically allocate money by injury and exposure. On another, the Supreme Court rules for Bayer on federal preemption and largely shuts the door on the failure-to-warn claims that drive the cases, potentially making the settlement moot and ending the litigation on the company's terms. And there are paths in between, a narrow ruling, a partial settlement, continued individual trials for those who opt out.

For anyone tracking this, those two events, the settlement's approval fate and the Supreme Court's decision, are the dominoes everything else depends on, and both are live in 2026. A practical fact rather than advice: statutes of limitations for these claims vary by state and run from when a person reasonably connected their lymphoma to glyphosate exposure, and the settlement's opt-out deadlines added their own time pressures for those wanting to preserve individual claims. We'll update this as the Supreme Court rules and as the settlement clears or fails its approval process, because after years of grinding trials, those are the developments that will finally determine which way the Roundup litigation turns.